Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT

From BugSigDB
Needs review
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, Turroni S, Centanni M, Severgnini M, Peano C, de Bellis G, Basaglia G, Gotti R, Masetti R, Pession A, Brigidi P, Candela M
Journal
Bone marrow transplantation
Year
2015
Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.

Experiment 1


Needs review

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks

Subjects

Location of subjects
Italy
Host species Species from which microbiome was sampled (if applicable)
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
graft versus host disease disease, graft-versus-host,disease, graft-VS-host,disease, homologous wasting,disease, runt,diseases, graft-versus-host,diseases, graft-VS-host,graft versus host disease,graft VS host disease,graft VS. host disease,graft-versus-host disease,graft-versus-host disease, resistance to,graft-versus-host disease, susceptibility to,graft-versus-host diseases,graft-versus-host-disease,graft-VS-host disease,graft-VS-host diseases,GVH,GVHD,GVHDS,homologous wasting disease,runt disease
Group 0 name Corresponds to the control (unexposed) group for case-control studies
pre- engraftment
Group 1 name Corresponds to the case (exposed) group for case-control studies
post- engraftment
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
malignant or non-malignant disease patients from four transplantation centers (Bologna, Pavia, Rome and Verona) that underwent allogeneic hematopoietic stem cell transplant with or without myeloablative conditioning regimen, who did not develop acute graft-versus-host disease post- enrichment
Group 0 sample size Number of subjects in the control (unexposed) group
17
Group 1 sample size Number of subjects in the case (exposed) group
17

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes


Signature 1

Needs review

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): WikiWorks

Source: Figure 3b, c, d, and supplemental table S1, text

Description: Average relative abundances in pre-HSCT and engrafment samples, of the main discriminant genera between the two time points in subjects who did not develop acute graft-versus- host disease (non-aGvHD)

Abundance in Group 1: decreased abundance in post- engraftment

NCBI Quality ControlLinks
Blautia
Dorea
Roseburia
Faecalibacterium
Oscillospira

Revision editor(s): WikiWorks

Experiment 2


Needs review

Curated date: 2021/01/10

Curator: WikiWorks

Revision editor(s): WikiWorks

Differences from previous experiment shown

Subjects

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
malignant or non-malignant disease patients from four transplantation centers (Bologna, Pavia, Rome and Verona) that underwent allogeneic hematopoietic stem cell transplant with or without myeloablative conditioning regimen, who developed skin acute graft-versus-host disease post- enrichment
Group 0 sample size Number of subjects in the control (unexposed) group
13
Group 1 sample size Number of subjects in the case (exposed) group
13

Lab analysis

Statistical Analysis

Signature 1

Needs review

Curated date: 2021/01/10

Curator: William Lam

Revision editor(s): WikiWorks

Source: Figure 3b, c, d, and supplemental table S1, text

Description: Average relative abundances in pre-HSCT and engrafment samples, of the main discriminant genera between the two time points in subjects who developed acute graft-versus- host disease (I-II grade) at a skin level (Skin aGvHD)

Abundance in Group 1: decreased abundance in post- engraftment

NCBI Quality ControlLinks
Bifidobacterium
Coprococcus
Dorea
Lachnospira
Roseburia
Ruminococcus
Oscillospira

Revision editor(s): WikiWorks